摘要
1名54岁男性失代偿期肝硬化患者,皮下注射重组人粒细胞集落刺激因子(rhG-CSF)200μg,1次/d。用药后第2天患者出现尿色变深,第4天出现眼睑水肿,肉眼血尿、少尿等症状。BUN由4.8mmol/L升至7.9mmol/L(最高13.9mmol/L),Cr由113μmol/L升至154μmol/L(最高308μmol/L)。停用rhG-CSF,给予还原型谷胱甘肽、硫普罗宁、呋塞米等对症支持治疗。2周后肾功能恢复正常。
A 54-year-old man with decompensated cirrhosis was given recombinant human granulocyte colony stimulating factor （rhG-CSF） 200μg once daily subcutaneously. The next day, dark urine occurred. On day 4, he developed palpebral oedema, gross hematuria, and oliguria. His level of BUN increased from 4.8 mmol/L to 7.9 mmol/L （ maximum ： 13.9 mmol/L） , and the level of Cr increased from 113μmol/L to 154 pznol/L （maximum： 308μmol/L）, rhG-CSF was withdrawn. The patient was treated with reduced glutathione, tiopronin, furosemide, and symptomatic and supportive treatment. Two weeks later, the patient＇s renal function returned to normal limits.
出处
《药物不良反应杂志》
2007年第5期357-357,共1页
Adverse Drug Reactions Journal
关键词
重组人粒细胞集落刺激因子
急性肾衰竭
recombinant human granulocyte colony stimulating fator （rhG-CSF）
acute renal failure
